MASS vs. ANGO, PYXS, UTMD, ALDX, MGX, NPCE, OMER, TSVT, GTHX, and FHTX
Should you be buying 908 Devices stock or one of its competitors? The main competitors of 908 Devices include AngioDynamics (ANGO), Pyxis Oncology (PYXS), Utah Medical Products (UTMD), Aldeyra Therapeutics (ALDX), Metagenomi (MGX), NeuroPace (NPCE), Omeros (OMER), 2seventy bio (TSVT), G1 Therapeutics (GTHX), and Foghorn Therapeutics (FHTX). These companies are all part of the "medical" sector.
908 Devices (NASDAQ:MASS) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
AngioDynamics has a net margin of -60.21% compared to 908 Devices' net margin of -68.57%. AngioDynamics' return on equity of -3.48% beat 908 Devices' return on equity.
908 Devices has higher earnings, but lower revenue than AngioDynamics. 908 Devices is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 27.8% of 908 Devices shares are owned by company insiders. Comparatively, 5.1% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
908 Devices has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
In the previous week, 908 Devices had 10 more articles in the media than AngioDynamics. MarketBeat recorded 10 mentions for 908 Devices and 0 mentions for AngioDynamics. 908 Devices' average media sentiment score of 1.08 beat AngioDynamics' score of 0.00 indicating that 908 Devices is being referred to more favorably in the media.
908 Devices currently has a consensus price target of $14.00, indicating a potential upside of 104.38%. AngioDynamics has a consensus price target of $14.25, indicating a potential upside of 135.93%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than 908 Devices.
AngioDynamics received 345 more outperform votes than 908 Devices when rated by MarketBeat users. However, 61.54% of users gave 908 Devices an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
Summary
AngioDynamics beats 908 Devices on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
908 Devices Competitors List
Related Companies and Tools
